Pulmonary hypertension (PH) is a pathophysiological condition characterized by elevated pulmonary arterial pressure. It's a progressive disease with a high morbidity and mortality rate, making comprehensive understanding crucial for optimal patient management.
PH can be idiopathic, heritable, or associated with various conditions such as connective tissue diseases, congenital heart disease, portal hypertension, and HIV infection. The World Health Organization (WHO) classifies PH into five groups based on etiology, clinical presentation, hemodynamic characteristics, and treatment strategy.
PH often presents non-specifically, with symptoms such as dyspnea, fatigue, and chest discomfort. As the disease progresses, signs of right heart failure may become evident. A high index of suspicion is required for early diagnosis.
The diagnosis of PH involves a combination of clinical assessment, echocardiography, and right heart catheterization. Other tests, such as pulmonary function tests, a six-minute walk test, and cardiac MRI, can provide additional information about the severity and prognosis of the disease.
Treatment strategies for PH are complex and largely depend on the underlying cause. General measures include supplemental oxygen, diuretics, and anticoagulation. Specific therapies include endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and prostacyclin analogs. In severe cases, lung transplantation may be considered.
Prognosis varies widely depending on the cause and severity of PH. Despite advances in treatment, PH remains a serious condition with a significant impact on quality of life and survival.
Understanding the fundamentals of PH is essential for healthcare professionals. Early recognition, comprehensive evaluation, and individualized treatment can significantly improve patient outcomes. Continuous research is needed to expand our knowledge and develop more effective therapies for this challenging disease.
1.
A Lot Can Be Said About You by Including Yourself in Photos.
2.
A new blood test greatly increases the ability to detect cancer.
3.
Novel biomarker has potential for predicting and treating skin cancer metastasis
4.
Anti-PD-L1 Plus Targeted Agent No Better Than Chemo for Resistant NSCLC
5.
No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer
1.
Preventing Heparin Induced Thrombocytopenia: Tips for Successful Anticoagulation Therapy
2.
Preventing Treatment-Related Secondary Malignancies: Evidence-Based Strategies for Clinical Practice
3.
Contemporary Frameworks in Oncology Across Clinical Settings
4.
What is Mullerian and How Does it Affect Your Health
5.
The Expanding Horizon of PSMA: A Comparative Clinical Review of Theranostics in Prostate Cancer and Beyond
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Understanding Common Causes of Abnormal Blood Counts
2.
Understanding Early Relapse in B-cell ALL: Rates, Risks, and Common Sites
3.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
4.
Understanding Cancer: Early Detection and Treatment
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part IV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation